Pieter Gillard, V. Huurman, Bart Van Der Auwera, B. Decallonne, Kris Poppe, B. Roep, Frans Gorus, C. Mathieu, Daniel Pipeleers, Bart Keymeulen
Objective: After an initially successful islet cell transplantation, a number of patients return to C-peptide-negativity and are therefore discontinued in immune suppressive therapy. Some were found to develop Graves' disease. Research design and methods: Immune suppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease. Results: In 4 patients clinical Graves' hyperthyroidism was observed within 21 months after discontinuation, and 30 to 71 months after start of immune suppressive therapy. All four exhibited a pretransplant positivity for thyroid peroxidase (TPO)-autoantibodies while the nine others were TPO-negative pre- and posttransplantation. Conclusions: Type 1 diabetic recipients of islet cell grafts with pretransplant TPO-autoantibody positivity exhibit a high risk for developing Graves' hyperthyroidism after immune suppressive therapy is discontinued for a failing graft.
Gillard, P, Huurman, V, Van Der Auwera, B, Decallonne, B, Poppe, K, Roep, B, Gorus, F, Mathieu, C, Pipeleers, D & Keymeulen, B 2009, 'Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies.', Diabetes Care, vol. 32, pp. 1817-1819. <http://care.diabetesjournals.org/content/32/10/1817.long>
Gillard, P., Huurman, V., Van Der Auwera, B., Decallonne, B., Poppe, K., Roep, B., Gorus, F., Mathieu, C., Pipeleers, D., & Keymeulen, B. (2009). Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care, 32, 1817-1819. http://care.diabetesjournals.org/content/32/10/1817.long
@article{c94968f49fe143678925cfbc25087519,
title = "Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies.",
abstract = "Objective: After an initially successful islet cell transplantation, a number of patients return to C-peptide-negativity and are therefore discontinued in immune suppressive therapy. Some were found to develop Graves' disease. Research design and methods: Immune suppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease. Results: In 4 patients clinical Graves' hyperthyroidism was observed within 21 months after discontinuation, and 30 to 71 months after start of immune suppressive therapy. All four exhibited a pretransplant positivity for thyroid peroxidase (TPO)-autoantibodies while the nine others were TPO-negative pre- and posttransplantation. Conclusions: Type 1 diabetic recipients of islet cell grafts with pretransplant TPO-autoantibody positivity exhibit a high risk for developing Graves' hyperthyroidism after immune suppressive therapy is discontinued for a failing graft.",
keywords = "Graves, hyperthyroidism, type 1 diabetes",
author = "Pieter Gillard and V. Huurman and {Van Der Auwera}, Bart and B. Decallonne and Kris Poppe and B. Roep and Frans Gorus and C. Mathieu and Daniel Pipeleers and Bart Keymeulen",
year = "2009",
language = "English",
volume = "32",
pages = "1817--1819",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
}